Results 121 to 130 of about 46,143 (249)

Profound Thrombocytopenia and Dyspnea 11 Days After Cardiac Surgery

American Journal of Hematology, Volume 100, Issue 7, Page 1234-1239, July 2025.
Sebastian Vuong, Menaka Pai, Sarah Patterson, Theodore E. Warkentin   +3 more
wiley   +1 more source

Idiopathic combined, autoantibody-mediated ADAMTS-13/factor H deficiency in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in a 17-year-old woman: a case report

Journal of Medical Case Reports, 2011
Introduction Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome is a life-threatening condition with various etiopathogeneses. Without therapy approximately 90% of all patients die from the disease. Case presentation We report the case of a 17-
Patschan Daniel, Korsten Peter, Behlau Arne, Vasko Radovan, Heeg Malte, Sweiss Nadera, Müller Gerhard A, Koziolek Michael   +7 more
doaj   +1 more source

Purpura: TTP [PDF]

, 2009
This issue of eMedRef provides information to clinicians on the pathophysiology, diagnosis, and therapeutics of thrombotic thrombocytopenic ...
Dudgikar, Darshana
core  

Eculizumab for Gemcitabine-Induced Hemolytic Uremic Syndrome: A Novel Therapy for an Emerging Condition [PDF]

, 2015
Introduction Atypical hemolytic uremic syndrome (aHUS), a thrombotic microangiopathy (TMA), is a disease characterized by hemolytic anemia, thrombocytopenia, and renal impairment. Gemcitabine, a commonly used chemotherapy, is emerging as a cause of aHUS.
Karkowsky, MD, Raphael, Parikh, MD, Kinjal   +1 more
core   +2 more sources

Caplacizumab Therapy without Plasma Exchange for Acquired Thrombotic Thrombocytopenic Purpura.

New England Journal of Medicine, 2019
Managing Acquired TTP without Plasma Exchange A case of acquired thrombotic thrombocytopenic purpura is reported in a Jehovah’s Witness who had neurologic manifestations but would not accept plasma...
Deepak P. Chander, M. Loch, S. Cataland, J. George   +3 more
semanticscholar   +1 more source

Complement and cytokine response in acute Thrombotic Thrombocytopenic Purpura [PDF]

, 2013
Complement dysregulation is key in the pathogenesis of atypical Haemolytic Uraemic Syndrome (aHUS), but no clear role for complement has been identified in Thrombotic Thrombocytopenic Purpura (TTP).
Heelas, E, Langley, K, Machin, SJ, Scully, M, Westwood, JP   +4 more
core   +1 more source

Clinical pharmacology of caplacizumab for the treatment of patients with acquired thrombotic thrombocytopenic purpura

Expert Review of Clinical Pharmacology, 2019
Introduction: Caplacizumab is a humanized anti-von Willebrand Factor (vWF) Nanobody® for the treatment of acquired Thrombotic Thrombocytopenic Purpura (aTTP). Caplacizumab targets the A1-domain of vWF, inhibiting the interaction between vWF and platelets.
M. Sargentini‐Maier, Philip De Decker, C. Tersteeg, J. Canvin, F. Callewaert, H. de Winter   +5 more
semanticscholar   +1 more source

Conformational activation of ADAMTS13 [PDF]

, 2014
A disintegrin and metalloprotease with thrombospondin motifs 13 (ADAMTS13) is a metalloprotease that regulates von Willebrand factor (VWF) function. ADAMTS13-mediated proteolysis is determined by conformational changes in VWF, but also may depend on its ...
Collins, RF, Crawley, JTB, Deforche, L, Lane, DA, Luken, BM, Phillips, R, South, K, Thomas, M, Vanhoorelbeke, K   +8 more
core   +1 more source

Thrombotic thrombocytopenic purpura: diagnostic criteria, clinical features, and long-term outcomes from 1995 through 2015.

Blood Advances, 2017
Our objective was to describe new observations from the Oklahoma Thrombotic Thrombocytopenic Purpura (TTP) Registry experience (November 1995 through December 2015) on the diagnosis of TTP along with patients' clinical features and their outcomes.
E. E. Page, J. K. Kremer Hovinga, Deirdra R. Terrell, S. Vesely, J. George   +4 more
semanticscholar   +1 more source

Persistence of circulating ADAMTS13-specific immune complexes in patients with acquired thrombotic thrombocytopenic purpura

Haematologica, 2014
Anti-ADAMTS13 autoantibodies are the main cause of acquired thrombotic thrombocytopenic purpura. Binding of these antibodies to ADAMTS13 eventually results in the formation of antigen-antibody immune complexes.
Silvia Ferrari, Kristina Palavra, Bernadette Gruber, Johanna A. Kremer Hovinga, Paul Knöbl, Claudine Caron, Caroline Cromwell, Louis Aledort, Barbara Plaimauer, Peter L. Turecek, Hanspeter Rottensteiner, Friedrich Scheiflinger   +11 more
doaj   +1 more source